Xin Hongqi, Katakowski Mark, Wang Fengjie, Qian Jian-Yong, Liu Xian Shuang, Ali Meser M, Buller Benjamin, Zhang Zheng Gang, Chopp Michael
From the Department of Neurology, Henry Ford Hospital, Detroit, MI (H.X., M.K., F.W., J.-Y.Q., X.S.L., M.M.A., B.B., Z.G.Z., M.C.); and Department of Physics, Oakland University, Rochester, MI (M.C.).
Stroke. 2017 Mar;48(3):747-753. doi: 10.1161/STROKEAHA.116.015204.
Multipotent mesenchymal stromal cell (MSC) harvested exosomes are hypothesized as the major paracrine effectors of MSCs. In vitro, the miR-17-92 cluster promotes oligodendrogenesis, neurogenesis, and axonal outgrowth. We, therefore, investigated whether the miR-17-92 cluster-enriched exosomes harvested from MSCs transfected with an miR-17-92 cluster plasmid enhance neurological recovery compared with control MSC-derived exosomes.
Rats subjected to 2 hours of transient middle cerebral artery occlusion were intravenously administered miR-17-92 cluster-enriched exosomes, control MSC exosomes, or liposomes and were euthanized 28 days post-middle cerebral artery occlusion. Histochemistry, immunohistochemistry, and Golgi-Cox staining were used to assess dendritic, axonal, synaptic, and myelin remodeling. Expression of phosphatase and tensin homolog and activation of its downstream proteins, protein kinase B, mechanistic target of rapamycin, and glycogen synthase kinase 3β in the peri-infarct region were measured by means of Western blots.
Compared with the liposome treatment, both exosome treatment groups exhibited significant improvement of functional recovery, but miR-17-92 cluster-enriched exosome treatment had significantly more robust effects on improvement of neurological function and enhancements of oligodendrogenesis, neurogenesis, and neurite remodeling/neuronal dendrite plasticity in the ischemic boundary zone (IBZ) than the control MSC exosome treatment. Moreover, miR-17-92 cluster-enriched exosome treatment substantially inhibited phosphatase and tensin homolog, a validated miR-17-92 cluster target gene, and subsequently increased the phosphorylation of phosphatase and tensin homolog downstream proteins, protein kinase B, mechanistic target of rapamycin, and glycogen synthase kinase 3β compared with control MSC exosome treatment.
Our data suggest that treatment of stroke with tailored exosomes enriched with the miR-17-92 cluster increases neural plasticity and functional recovery after stroke, possibly via targeting phosphatase and tensin homolog to activate the PI3K/protein kinase B/mechanistic target of rapamycin/glycogen synthase kinase 3β signaling pathway.
多能间充质基质细胞(MSC)分泌的外泌体被认为是MSC主要的旁分泌效应物。在体外,miR-17-92簇可促进少突胶质细胞生成、神经发生和轴突生长。因此,我们研究了与对照MSC来源的外泌体相比,用miR-17-92簇质粒转染的MSC收获的富含miR-17-92簇的外泌体是否能增强神经功能恢复。
对经历2小时短暂大脑中动脉闭塞的大鼠静脉注射富含miR-17-92簇的外泌体、对照MSC外泌体或脂质体,并在大脑中动脉闭塞后28天实施安乐死。采用组织化学、免疫组织化学和高尔基-考克斯染色评估树突、轴突、突触和髓鞘重塑。通过蛋白质印迹法检测梗死周边区域中磷酸酶和张力蛋白同源物(PTEN)的表达及其下游蛋白蛋白激酶B(AKT)、雷帕霉素靶蛋白(mTOR)和糖原合酶激酶3β(GSK3β)的激活情况。
与脂质体治疗相比,两个外泌体治疗组的功能恢复均有显著改善,但与对照MSC外泌体治疗相比,富含miR-17-92簇的外泌体治疗对改善神经功能以及增强缺血边界区(IBZ)的少突胶质细胞生成、神经发生和神经突重塑/神经元树突可塑性具有更显著的作用。此外,与对照MSC外泌体治疗相比,富含miR-17-92簇的外泌体治疗显著抑制了经证实的miR-17-92簇靶基因PTEN,并随后增加了PTEN下游蛋白AKT、mTOR和GSK3β的磷酸化水平。
我们的数据表明,用富含miR-17-92簇的定制外泌体治疗中风可增加中风后的神经可塑性和功能恢复,可能是通过靶向PTEN激活PI3K/AKT/mTOR/GSK3β信号通路实现的。